We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HSIC Stock Benefits From Expanded Partnership With vVARDIS
Read MoreHide Full Article
Key Takeaways
Henry Schein expanded its vVARDIS deal, securing exclusive U.S. distribution of Curodont from 2026.
HSIC shares inched higher as the partnership is expected to strengthen the company's Dental business.
The expansion lets Henry Schein reach general, orthodontic, and pediatric care with wider Curodont access.
Henry Schein, Inc. (HSIC - Free Report) recently expanded its agreement with vVARDIS and gained the exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus (Curodont) product across all dental market segments, effective Jan. 1, 2026.
The partnership is expected to bolster the company’s Dental business.
HSIC Stock’s Likely Trend Following the News
Since the announcement, HSIC shares have risen 0.1%, closing at $73.15 in after-market trading session yesterday.
The company’s revenue growth has been consistently supported by niche acquisitions and partnerships. Accordingly, we expect the news to help support a rebound in the stock’s movement. In line with this, in August, Henry Schein inked a strategic partnership with Oral Genome, a leading innovator in salivary testing. The collaboration is aimed at bringing Oral Genome’s cutting-edge point-of-care saliva testing nationwide through Henry Schein’s distribution channels. Accordingly, we expect the latest news to maintain the stock’s positive momentum.
Henry Schein has a market capitalization of $8.78 billion at present. Going by the Zacks Consensus Estimate, the company’s 2025 earnings per share (EPS) are expected to grow 3.6% over 2024. It delivered an average earnings surprise of 1.4% in the trailing four quarters.
Importance of Curodont
Curodont is a proprietary solution that treats patients with early-stage cavities with a drill and needle-free application. It is widely recognized that poor oral health can impact overall health, and untreated cavities can become life-threatening.
According to a study published in the International Journal of Epidemiology, people with fewer permanent teeth and untreated cavities were found to have higher all-cause and heart disease mortality. Up to 80% of patients have early-stage cavities, and until now, most have left the dental office without treatment, increasing the risk of more serious diseases. Curodont will empower dental practices to address this untapped opportunity by expanding patient care with a drill and needle-free approach.
More on HSIC’s Expanded Partnership
The strategic expansion builds on Henry Schein’s 2024 exclusivity agreement with vVARDIS for Dental Service Organizations (DSOs). Beginning next year, the partnership will extend nationwide across multiple areas of dental care, including general dentistry, orthodontics and pediatric dentistry. This broader collaboration reflects both companies’ shared commitment to helping dental professionals run more efficient practices while advancing the oral and overall health of the communities they serve.
Image Source: Zacks Investment Research
Henry Schein is currently the market leader in selling Curodont to general practitioners and DSOs in the United States. The company also serves as the exclusive distributor of the product in the United Kingdom and holds non-exclusive distribution rights in other jurisdictions.
Industry Prospects Favor HSIC
Per Precedence Research’s report, the global dental caries treatment market size is predicted to increase from $8.01 billion in 2025 to approximately $12.11 billion by 2034, at a CAGR of 4.70% during 2025-2034. The rising prevalence of dental diseases globally requires proper treatment to avoid any critical illness in the oral cavity. The introduction and development of novel advanced treatment options for dental caries have resulted in the growth of the dental caries treatment market, which is expected to grow continuously.
Another Development by HSIC
Henry Schein’s dental software business, Henry Schein One, has unveiled natively embedded AI and automation workflows at the 2025 Greater New York Dental Meeting. This includes Voice Notes, which helps practices close revenue gaps through clean claims and modernize their operations more effectively.
HSIC Stock Price Performance
Year to date, shares of HSIC have rallied 5.7% compared with the industry’s 15.6% growth.
HSIC’s Zacks Rank and Top Picks
Henry Schein currently carries a Zacks Rank #3 (Hold).
Estimates for Globus Medical’s EPS have increased 11.8% in the past 30 days. Shares of the company have risen 8.5% in the past year compared with the industry’s growth of 1.1%. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific’s shares have jumped 12.3% in the past year. Estimates for the company’s 2025 EPS have increased 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
Estimates for MDT’s fiscal 2026 EPS of $5.65 have increased 0.5% in the past 30 days. Shares of the company have rallied 21.7% in the past year against the industry’s 0.1% decline. MDT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.7%. In the last reported quarter, it delivered an earnings surprise of 3.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HSIC Stock Benefits From Expanded Partnership With vVARDIS
Key Takeaways
Henry Schein, Inc. (HSIC - Free Report) recently expanded its agreement with vVARDIS and gained the exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus (Curodont) product across all dental market segments, effective Jan. 1, 2026.
The partnership is expected to bolster the company’s Dental business.
HSIC Stock’s Likely Trend Following the News
Since the announcement, HSIC shares have risen 0.1%, closing at $73.15 in after-market trading session yesterday.
The company’s revenue growth has been consistently supported by niche acquisitions and partnerships. Accordingly, we expect the news to help support a rebound in the stock’s movement. In line with this, in August, Henry Schein inked a strategic partnership with Oral Genome, a leading innovator in salivary testing. The collaboration is aimed at bringing Oral Genome’s cutting-edge point-of-care saliva testing nationwide through Henry Schein’s distribution channels. Accordingly, we expect the latest news to maintain the stock’s positive momentum.
Henry Schein has a market capitalization of $8.78 billion at present. Going by the Zacks Consensus Estimate, the company’s 2025 earnings per share (EPS) are expected to grow 3.6% over 2024. It delivered an average earnings surprise of 1.4% in the trailing four quarters.
Importance of Curodont
Curodont is a proprietary solution that treats patients with early-stage cavities with a drill and needle-free application. It is widely recognized that poor oral health can impact overall health, and untreated cavities can become life-threatening.
According to a study published in the International Journal of Epidemiology, people with fewer permanent teeth and untreated cavities were found to have higher all-cause and heart disease mortality. Up to 80% of patients have early-stage cavities, and until now, most have left the dental office without treatment, increasing the risk of more serious diseases. Curodont will empower dental practices to address this untapped opportunity by expanding patient care with a drill and needle-free approach.
More on HSIC’s Expanded Partnership
The strategic expansion builds on Henry Schein’s 2024 exclusivity agreement with vVARDIS for Dental Service Organizations (DSOs). Beginning next year, the partnership will extend nationwide across multiple areas of dental care, including general dentistry, orthodontics and pediatric dentistry. This broader collaboration reflects both companies’ shared commitment to helping dental professionals run more efficient practices while advancing the oral and overall health of the communities they serve.
Image Source: Zacks Investment Research
Henry Schein is currently the market leader in selling Curodont to general practitioners and DSOs in the United States. The company also serves as the exclusive distributor of the product in the United Kingdom and holds non-exclusive distribution rights in other jurisdictions.
Industry Prospects Favor HSIC
Per Precedence Research’s report, the global dental caries treatment market size is predicted to increase from $8.01 billion in 2025 to approximately $12.11 billion by 2034, at a CAGR of 4.70% during 2025-2034. The rising prevalence of dental diseases globally requires proper treatment to avoid any critical illness in the oral cavity. The introduction and development of novel advanced treatment options for dental caries have resulted in the growth of the dental caries treatment market, which is expected to grow continuously.
Another Development by HSIC
Henry Schein’s dental software business, Henry Schein One, has unveiled natively embedded AI and automation workflows at the 2025 Greater New York Dental Meeting. This includes Voice Notes, which helps practices close revenue gaps through clean claims and modernize their operations more effectively.
HSIC Stock Price Performance
Year to date, shares of HSIC have rallied 5.7% compared with the industry’s 15.6% growth.
HSIC’s Zacks Rank and Top Picks
Henry Schein currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) . While Globus Medical sports a Zacks Rank #1 (Strong Buy), Boston Scientific and Medtronic carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Globus Medical’s EPS have increased 11.8% in the past 30 days. Shares of the company have risen 8.5% in the past year compared with the industry’s growth of 1.1%. GMED’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.2%. In the last reported quarter, it delivered an earnings surprise of 49.4%.
Boston Scientific’s shares have jumped 12.3% in the past year. Estimates for the company’s 2025 EPS have increased 1 cent to $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.
Estimates for MDT’s fiscal 2026 EPS of $5.65 have increased 0.5% in the past 30 days. Shares of the company have rallied 21.7% in the past year against the industry’s 0.1% decline. MDT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.7%. In the last reported quarter, it delivered an earnings surprise of 3.8%.